Lian Li1, Quan Jiang1, Chang Sheng Qu2, Guang Liang Ding1, Qing Jiang Li1, Shi Yang Wang3, Ji Hyun Lee3, Mei Lu4, Asim Mahmood2, Michael Chopp1,3
1Neurology, Henry Ford Hospital, Detroit, MI, United States; 2Neurosurgery, Henry Ford Hospital, Detroit, MI, United States; 3Physics, Oakland University, Rochester, MI, United States; 4Biostatistics & Research Epidemiology, Henry Ford Hospital, Detroit, MI, United States
Cell therapy promotes brain remodeling and improves functional recovery after various central nervous system disorders, including traumatic brain injury (TBI). We tested the hypothesis that treatment of TBI with intravenous administration of human marrow stromal cells (hMSCs) provides therapeutic benefit in modifying hemodynamic and structural abnormalities, which are detectable by in vivo MRI. Our data demonstrate that hMSCs administration following TBI diminishes hemodynamic abnormalities by early restoration and preservation of CBF in the brain regions adjacent to and remote from the impact site, and reduces generalized cerebral atrophy, all of which may contribute to the observed improvement of functional outcome.